Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ IRAK4 Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA529699
Description
Recommended positive controls: H1299. Predicted reactivity: Mouse (89%), Rat (90%), Pig (95%), Sheep (93%), Rhesus Monkey (100%), Bovine (94%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
IL-1 receptor associated kinases (IRAKs) are serine/threonine kinases involved in signaling via Toll/IL-1 pathways. Overexpression of IRAK-4 activates NF-kappa-B and MAPK pathways. IRAK-4 interacts with and phosphorylates IRAK-1. IRAK-4-deficient animals are completely resistant to the challenge with LPS. Animals and humans lacking IRAK-4 are impaired in their responses to viral and bacterial challenges. Members in IRAK/Pelle family play a central role in IL-1R/TLR mediated inflammatory responses and in innate immunity.
Specifications
IRAK4 | |
Polyclonal | |
Unconjugated | |
IRAK4 | |
8430405M07Rik; 9330209D03Rik; interleukin 1 receptor associated kinase 4; interleukin-1; interleukin-1 receptor-associated kinase 4; IPD1; Irak4; IRAK-4; NY-REN-64; REN64; renal carcinoma antigen NY-REN-64 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
51135 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
0.54 mg/mL | |
0.1M tris glycine with 10% glycerol and 0.01% thimerosal; pH 7 | |
Q9NWZ3 | |
IRAK4 | |
Recombinant protein encompassing a sequence within the center region of human IRAK4. The exact sequence is proprietary. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction